Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - BioTransplant Incorp. (NasdaqNM:BTRN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Recent Events
Aug 10Earnings Announcement
Location
Charlestown Navy Yard
Building 75 Third Avenue
Charlestown, MA 02129
Phone: (617) 241-5200
Fax: (617) 241-8780
Employees (last reported count): 62
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 30%
·Institutional: 34% (48% of float)
(41 institutions)
·Net Inst. Selling: 39.0K shares (+0.59%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
BioTransplant Incorporated is developing pharmaceutical products and systems to enable the body's immune system to better tolerate the transplantation of foreign cells, tissues and organs. Its lead product, MEDI-507, is being developed in collaboration with MedImmune, Inc. The Company is also independently developing other proprietary technology, which it refers to as ImmunoCognance technology. This technology is based upon mixing elements of a donor's immune system with that of a patient in a manner that enables the patient to recognize the donor's tissues as if those foreign tissues belonged to the patient. Based upon its ImmunoCognance technology, the Company is developing a portfolio of products designed to improve therapies associated with organ and bone marrow transplantation, as well as to improve the treatment of cancer, autoimmune diseases and blood disorders.
More from Market Guide: Expanded Business Description

Financial Summary
BioTransplant Incorporated develops proprietary anti-rejection pharmaceuticals and organ transplantation systems, which represent a comprehensive approach to inducing long-term specific transplantation tolerance in humans. For the three months ended 3/31/01, revenues totaled $0, down from $1.5 million. Net loss fell 7% to $2.3 million. Revenues reflect the termination of research agreement. Net loss reflects decreased R&D expenses due to reimbursements.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, after tax earnings were -3,703. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Elliot Lebowitz, Ph.D., 60
Chairman, CEO
$309K--  
Walter Ogier, 44
Pres, COO, Director
--  --  
James Hope, Ph.D., 49
Sr. VP of Devel.
229K$146K
Mary White-Scharf, Ph.D., 50
Sr. VP, Research
191K147K
Richard Capasso, 39
VP, Fin. and Treasurer
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:BTRNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 16-Mar-2001
$2.969
Recent Price$5.20 
52-Week High
on 3-Oct-2000
$18.50 
Beta-0.02 
Daily Volume (3-month avg)81.4K
Daily Volume (10-day avg)40.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-62.7%
52-Week Change
relative to S&P500
-49.9%
Share-Related Items
Market Capitalization$102.8M
Shares Outstanding19.8M
Float13.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$1.03 
Earnings (ttm)-$1.03 
Earnings (mrq)-$0.26 
SalesN/A 
Cash (mrq*)$0.87 
Valuation Ratios
Price/Book (mrq*)5.06 
Price/EarningsN/A 
Price/SalesN/A 
Income Statements
SalesN/A 
EBITDA (ttm*)-$12.2M
Income available to common (ttm)-$12.8M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-65.41%
Return on Equity (ttm)-78.76%
Financial Strength
Current Ratio (mrq*)5.92 
Debt/Equity (mrq*)0.04 
Total Cash (mrq)$19.1M
Short Interest
As of 8-Aug-2001
Shares Short825.0K
Percent of Float6.0%
Shares Short
(Prior Month)
709.0K
Short Ratio8.78 
Daily Volume94.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.